Publications
132
Citations
1,215
Est. group size
~7
Recurring co-author estimate
Active years
8
Publishing since 2019
Typically publishes in teams of ~20 · 0% small-team papers (≤3 authors) · across 14 venues
- Safety outcomes with tremelimumab (T) rechallenge in the phase 3 HIMALAYA study of T plus durvalumab (D) in unresectable hepatocellular carcinoma.
Journal of Clinical Oncology · 2026
- A phase II randomized study of atezolizumab plus multikinase inhibitor (MKI) versus MKI alone in patients with advanced hepatocellular carcinoma previously treated with atezolizumab plus bevacizumab (Atezo/Bev).
Journal of Clinical Oncology · 2026
- Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial
RWTH Publications (RWTH Aachen) · 2026
- 33 - ANÁLISIS DE LOS TRATAMIENTOS SUBSIGUIENTES ANTINEOPLÁSICOS DEL ESTUDIO DE FASE 3 HIMALAYA: TREMELIMUMAB MÁS DURVALUMAB EN EL CARCINOMA HEPATOCELULAR AVANZADO O IRRESECABLE
Gastroenterología y Hepatología · 2026
- Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer)
Figshare · 2026
- Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer)
Future Oncology · 2026
- Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer)
Figshare · 2026
- Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
Journal of Hepatology · 2025
- Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial
Hepatology · 2025
- Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, CHS-388) in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).
Journal of Clinical Oncology · 2025
- Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Zeitschrift für Gastroenterologie · 2025
- 404: FIVE-YEAR OVERALL SURVIVAL (OS) AND OS BY BASELINE LIVER FUNCTION FROM THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB (T) PLUS DURVALUMAB (D) IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC)
Gastroenterology · 2025
- Su1751: FIVE-YEAR OVERALL SURVIVAL (OS) AND OS BY TUMOR RESPONSE MEASURES FROM THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB PLUS DURVALUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC)
Gastroenterology · 2025
- Five-year overall survival (OS) and OS by baseline liver function from the Phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Zeitschrift für Gastroenterologie · 2025
- Subsequent anticancer therapy analysis of the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Zeitschrift für Gastroenterologie · 2025
- Journal of Clinical Oncology×15
- Annals of Oncology×6
- Journal of Hepatology×3
- Zeitschrift für Gastroenterologie×3
- Journal of the National Comprehensive Cancer Network×2
- Abhinav Achreja
Medicine · University of Michigan
- Olamide Animasahun
Medicine · University of Michigan
- Arathi Mohan
Medicine · University of Michigan
- Carlo Pulitanò
Medicine · The Ohio State University
- G.A. Poultsides
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile